Insider Buying: Vanda Pharmaceuticals (NASDAQ:VNDA) Director Acquires $13,167.54 in Stock

by · The Cerbat Gem

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) Director Charles Duncan bought 3,447 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were bought at an average cost of $3.82 per share, for a total transaction of $13,167.54. Following the completion of the transaction, the director directly owned 102,898 shares of the company’s stock, valued at $393,070.36. This trade represents a 3.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Charles Cliff Duncan also recently made the following trade(s):

  • On Thursday, November 5th, Charles Duncan bought 5,803 shares of Vanda Pharmaceuticals stock. The shares were bought at an average cost of $3.80 per share, with a total value of $22,051.40.
  • On Tuesday, November 3rd, Charles Duncan purchased 750 shares of Vanda Pharmaceuticals stock. The stock was bought at an average price of $3.80 per share, with a total value of $2,850.00.

Vanda Pharmaceuticals Trading Up 6.4%

Shares of VNDA opened at $3.82 on Friday. The business’s 50-day moving average price is $4.63 and its 200 day moving average price is $6.12. The stock has a market capitalization of $231.00 million, a P/E ratio of -0.83 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 1-year low of $3.57 and a 1-year high of $9.94. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. The firm had revenue of $69.81 million for the quarter, compared to the consensus estimate of $69.20 million. Analysts expect that Vanda Pharmaceuticals Inc. will post -2.53 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, November 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Wall Street Zen raised shares of Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 31st. Zacks Research upgraded shares of Vanda Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Finally, B. Riley Financial reiterated a “buy” rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Get Our Latest Analysis on Vanda Pharmaceuticals

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently bought and sold shares of VNDA. BlackRock Inc. purchased a new stake in Vanda Pharmaceuticals in the 2nd quarter worth about $46,841,000. Renaissance Technologies LLC boosted its position in Vanda Pharmaceuticals by 11.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock worth $25,979,000 after acquiring an additional 378,598 shares during the period. State Street Corp grew its stake in Vanda Pharmaceuticals by 16.6% during the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after acquiring an additional 500,843 shares in the last quarter. AIGH Capital Management LLC grew its stake in Vanda Pharmaceuticals by 37.6% during the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock valued at $19,002,000 after acquiring an additional 751,569 shares in the last quarter. Finally, Quantinno Capital Management LP grew its stake in Vanda Pharmaceuticals by 25.0% during the 1st quarter. Quantinno Capital Management LP now owns 327,193 shares of the biopharmaceutical company’s stock valued at $2,261,000 after acquiring an additional 65,391 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.

Featured Stories